NDAORALCAPSULE
Approved
Aug 2012
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
8/8 — Comprehensive
LINZESS (linaclotide) by AbbVie is guanylate cyclase activators [moa]. Approved for irritable bowel syndrome with constipation, chronic idiopathic constipation, chronic constipation and 1 more indications. First approved in 2012.
Drug data last refreshed 19h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LINZESS (linaclotide) is an oral guanylate cyclase-C agonist developed by AbbVie and approved in August 2012. The product treats irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) by activating guanylate cyclase-C receptors on intestinal epithelial cells to increase fluid secretion and accelerate transit. It represents a novel mechanism class distinct from traditional laxatives and osmotic agents, offering targeted GI motility enhancement.
$1.8BPart D
7.8 years to LOEMechanism of Action
Guanylate Cyclase Activators
Pharmacologic Class:
Guanylate Cyclase-C Agonist
Worked on LINZESS at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.